Staburo biostatistics support in diabetes trial
Another publication with Staburo biostatistics support, this time in diabetes type 2.
Background: Studies of dipeptidyl peptidase (DPP)-4 inhibitors report heterogeneous effects on endothelial function in patients with type 2 diabetes (T2D). This study assessed the effects of the DPP-4 inhibitor linagliptin versus the sulphonylurea glimepiride and placebo on measures of macro- and microvascular endothelial function in patients with T2D who represented a primary cardiovascular disease prevention population.
The full publication can be found here: https://cardiab.biomedcentral.com/articles/10.1186/s12933-016-0493-3
Feel free to reach out to us if you need support in your study!